I'm focused on the efficacy of PSI-7977/SOC in GT2/GT3 patients going into AASLD this November. The company continues to shorten the treatment duration (with one cohort down to 8 weeks) in what the CEO calls a game of limbo. At some point the drug combo will lose the 100% efficacy seen at 12 weeks but if all patients in the 8 week cohort achieve SVR's it would be unprecedented and the FDA may be willing to bring the drug to market early for the underserved GT2/GT3 market. There seems to be no safety or tolerability issues with this drug.
If this occurs even the most bullish analyst estimates may fall short next year.
News 
Market Data 
Discover 
